ICE Pharma acquires Iwaki manufacturing site from Mitbubishi API corporation
We are pleased to announce that on May 2nd ICE Pharma completed the purchase of the Iwaki Ursodeoxycholic Acid (“UDCA”) manufacturing site from Mitsubishi API Corporation. This transaction represents...
Third research publication in collaboration with ICE Pharma and Ferrier Research Institute
Synthesis of Novel C/D Ring Modified Bile Acids Bile acid receptors have been identified as important targets for the development of new therapeutics to treat various metabolic and inflammatory...
Bile acids in medicine. Review article by ICE Pharma
Bile acids: From acient Chinese medicines to modern treatments In 1999 the landscape evolved further when, bile acids and bile salts were shown to have hormonal activity as bile...
Second research publication in collaboration with ICE Pharma and Ferrier Research Institute
Synthesis of 12β-methyl-18-nor-avicholic acid analogues as potential TGR5 agonists In the quest for new modulators of the Farnesoid-X (FXR) and Takeda G-protein-coupled (TGR5) receptors, bile acids are a popular...
ICE Pharma acquires ABC Farmaceutici S.p.A.
We are pleased to announce that on December 15th ICE Pharma completed the acquisition of ABC Farmaceutici S.p.A. (“ABC”). ABC is a pharmaceutical company based in Ivrea, Italy. Founded...
First research publication in collaboration with ICE Pharma and Ferrier Research Institute
Synthesis of 12β-Methyl-18-nor-bile Acids Decoupling the roles of the farnesoid X nuclear receptor and Takeda G-protein-coupled bile acid receptor 5 is essential for the development of novel bile acid...
ICE Pharma Cogenerator Project in Basaluzzo manufacturing site
In May 2019 the cogenerator project was ended and realized. Project was supported by POS FESR PIEMONTE 2014-2020. The principal goals of the project were: Reduction of energy costs...